Legend Biotech (LEGN) Operating Income (2024 - 2025)
Legend Biotech (LEGN) posted Operating Income of -$19.7 million for Q4 2025, up 54.66% on a QoQ basis from -$43.5 million in Q3 2025, and up 75.16% year-over-year from -$11.2 million in Q4 2024.
Legend Biotech (LEGN) Operating Income (2024 - 2025) Analysis & Trends
Legend Biotech's Operating Income history runs 2 years deep, the most recent figure standing at -$19.7 million for Q4 2025.
- Quarterly Operating Income rose 75.16% year-over-year to -$19.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$212.8 million (changed N/A YoY) and the FY2025 annual result came in at -$136.5 million, up 55.9% from the prior year.
- Operating Income was -$19.7 million for Q4 2025 at Legend Biotech, up from -$43.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$19.7 million in Q4 2025 and bottomed at -$79.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Legend Biotech | 8.26 Bn | 7.36 Bn | - | -19.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19.70 Mn |
| Sep 30, 2025 | -43.45 Mn |
| Dec 31, 2024 | -79.30 Mn |
| Sep 30, 2024 | -70.36 Mn |